Edition:
United States

AbbVie Inc (ABBV.K)

ABBV.K on New York Consolidated

87.48USD
22 Sep 2017
Change (% chg)

$0.07 (+0.08%)
Prev Close
$87.41
Open
$87.22
Day's High
$87.75
Day's Low
$86.77
Volume
6,806,950
Avg. Vol
5,995,825
52-wk High
$89.69
52-wk Low
$55.06

Latest Key Developments (Source: Significant Developments)

AbbVie and Bristol-Myers Squibb announce clinical research collaboration to evaluate a therapeutic regimen in advanced solid tumors
Friday, 22 Sep 2017 06:59am EDT 

Sept 22 (Reuters) - AbbVie Inc :AbbVie and Bristol-Myers Squibb announce clinical research collaboration to evaluate a therapeutic regimen in advanced solid tumors.Bristol-Myers Squibb Co - ‍specific terms of agreement were not disclosed.​.Bristol-Myers Squibb Co - ‍AbbVie is sponsor conducting trial​.Bristol-Myers Squibb Co - ‍study could expand into additional solid tumors in future​.Bristol-Myers - collaboration to evaluate combination of abbVie's ABBV-399 and co's Opdivo in c-Met overexpressing non-small cell lung cancer​.  Full Article

AbbVie announces positive topline results from phase 3 trial evaluating Venclexta/Venclyxto tablets in combination with Rituxan
Monday, 18 Sep 2017 11:30am EDT 

Sept 18 (Reuters) - AbbVie Inc ::AbbVie announces positive topline results from phase 3 trial evaluating Venclexta™/Venclyxto™ (Venetoclax) tablets in combination with Rituxan® (Rituximab) for the treatment of patients with relapsed/refractory chronic lymphocytic Leukemia.Abbvie Inc - ‍Phase 3 Murano Study Of Venclexta venclyxto tablets in combination with rituxan met its primary endpoint​.Abbvie inc - ‍Venclexta/Venclyxto is being developed by AbbVie and Roche​.AbbVie Inc - ‍Safety data, including serious and most common adverse events and discontinuation rates, are currently being analyzed​.AbbVie - ‍Tumor lysis syndrome, including fatal events, has occurred in patients with previously treated CLL with high tumor burden on treating with Venclyxto​.  Full Article

AbbVie's upadacitinib meets all primary and ranked secondary endpoints
Monday, 11 Sep 2017 08:02am EDT 

Sept 11 (Reuters) - AbbVie Inc ::AbbVie's upadacitinib (ABT-494) meets all primary and ranked secondary endpoints in second phase 3 study in rheumatoid arthritis.AbbVie Inc - ‍safety profile of upadacitinib was consistent with previously reported studies, with no new safety signals detected​.AbbVie - ‍Select-beyond showed positive results with both doses (15 mg, 30 mg once-daily) meeting primary endpoints in difficult-to-treat patient population​.AbbVie Inc - ‍phase 3 trials of upadacitinib in psoriatic arthritis are ongoing​.  Full Article

Abbvie Inc says sets quarterly cash dividend of $0.64/shr
Friday, 8 Sep 2017 11:03am EDT 

Sept 8 (Reuters) - Abbvie Inc :Says ‍board of directors of Abbvie Inc declared a quarterly cash dividend of $0.64 per share​.Says Since 2013, Abbvie has increased its dividend by 60 percent .  Full Article

Coherus Biosciences says ‍PTAB denied 4 petitions for inter partes review of Abbvie's patent
Thursday, 7 Sep 2017 11:57am EDT 

Sept 7 (Reuters) - Coherus Biosciences Inc :Coherus Biosciences provides update on ‘619 IPR institution decision.Says ‍PTAB denied institution of all 4 petitions for inter partes review of Abbvie's patent related to Abbvie's Humira formulation​.  Full Article

Abbvie's upadacitinib meets primary endpoint in phase 2b study in atopic dermatitis
Thursday, 7 Sep 2017 08:03am EDT 

Sept 7 (Reuters) - Abbvie Inc :Abbvie's upadacitinib (abt-494) meets primary endpoint in phase 2b study in atopic dermatitis.Abbvie Inc - "‍look forward to advancing upadacitinib to phase 3 studies in 2018"​.Abbvie Inc - ‍upadacitinib is not approved by regulatory authorities and safety and efficacy have not been established​.Abbvie-‍results showed that primary, secondary endpoints, patients treated with upadacitinib achieved improvements that were statistically significant.Abbvie Inc - ‍in study, no new safety signals were detected​.  Full Article

Abbvie submits NDA to U.S. FDA for investigational oral treatment Elagolix for management of endometriosis with associated pain
Wednesday, 6 Sep 2017 08:01am EDT 

Sept 6 (Reuters) - Abbvie Inc ::Abbvie submits new drug application to U.S. FDA for investigational oral treatment Elagolix for the management of endometriosis with associated pain.Abbvie Inc - ‍submitted NDA to U.S. Food and drug administration for Elagolix​.  Full Article

Inventiva and AbbVie extend agreement
Monday, 4 Sep 2017 01:31am EDT 

Sept 4 (Reuters) - INVENTIVA SA ::INVENTIVA AND ABBVIE EXTEND AGREEMENT TO DISCOVER NEW POTENT ORALLY-AVAILABLE SMALL MOLECULE RORΓ INVERSE AGONIST DRUG CANDIDATES.INVENTIVA WILL RECEIVE AN UNDISCLOSED RESEARCH PAYMENT‍​.INVENTIVA WILL RECEIVE MILESTONE PAYMENTS WHEN A NEW CANDIDATE IS IDENTIFIED‍​.INVENTIVA WILL ALSO BE ELIGIBLE FOR DEVELOPMENT AND SALES MILESTONES AS WELL AS ROYALTIES ON SALES‍​.  Full Article

Abbvie says HUMIRA will now be reimbursed in British Columbia, Ontario, New Brunswick, Newfoundland, Labrador, Saskatchewan, Yukon
Tuesday, 29 Aug 2017 08:00am EDT 

Aug 29 (Reuters) - Abbvie Inc ::Abbvie Inc - HUMIRA will now be reimbursed in British Columbia, Ontario, New Brunswick, Newfoundland and Labrador, Saskatchewan and Yukon.Abbvie Inc - HUMIRA is also now covered by federal non-insured health benefits program.  Full Article

U.S. FDA says approved Abbvie's Mavyret for Hepatitis C
Thursday, 3 Aug 2017 03:22pm EDT 

Aug 3 (Reuters) - U.S. Food and Drug Administration ::FDA approves Mavyret for Hepatitis C ‍​.U.S. FDA- FDA granted the application priority review, breakthrough therapy designations, granted approval of Mavyret to Abbvie Inc ‍​.  Full Article

BRIEF-AbbVie and Bristol-Myers Squibb announce clinical research collaboration to evaluate a therapeutic regimen in advanced solid tumors

* AbbVie and Bristol-Myers Squibb announce clinical research collaboration to evaluate a therapeutic regimen in advanced solid tumors